Can you explain the "phase 3" slide?
QUOTE
======================================
Multi-center world wide study: efficacy
and safety in untreated patients with
significant symptoms of Gaucher Disease.
Protocol outline reviewed by FDA:
randomized, double blind, parallel groups,
dose-ranging study.
Measurable efficacy end point.
======================================
I could only see the half-life measurement in their p-1 study (no p-value, though). Is T/2 considered as EFFICACY end-point?
If not, what is the end point of the P-3 trial?
Market Data 
Markets 
AI
